Business Summary

The long term (10 - 15 year) vision of Integrated Medicines Ltd (IML) is one of healthcare systems that routinely provide personalised medicines.

To realise this vision, IML will employ a medium term strategy of demonstrating the overt benefits of integrating surrogates & diagnostics with the development & promotion of medicines to manufacturers, regulators, providers, and users of the proprietary medicines. Therefore, IML plans to contract with key pharmaceutical ("Pharma") and diagnostics ("Dx") companies to facilitate more widespread use of approved diagnostic tests in the promotion & marketing of medicines. IML will also promote exclusive adaption of diagnostic tests to facilitate approval & launch of late-stage new medicines. Finally, IML will work with Pharma and Dx to utilise clinically-validated surrogates in the development of new medicines. This latter activity will involve contracting, directly or indirectly, with additional business partners including surrogate/ biomarker discovery groups, central reference/testing labs ("CTLs")and contract R&D organisations ("CROs").

Thus, the short-term objectives of the IML plan are:

(1) to ensure that surrogates and diagnostics are considered for all new development programmes in the receptive therapeutic areas of oncology & infectious disease; and

(2) to aggressively promote development & uptake of surrogates in neurodegenerative & metabolic disease, where objective tests can have enormous impact and/or are greatly needed; and

(3) to match diagnostics technologies with new medicines being developed by key pharmaceutical companies in the above therapeutic areas.